L-1416, a novel MDR reversing agent with possible reduced calcium antagonism.

Zhou, Zaigang; Tang, Xiaolei; Zhang, Yifan; Hu, Zheyi; Wu, Jinhui; Hu, Yiqiao

Zhou, Zaigang; Tang, Xiaolei; Zhang, Yifan; Hu, Zheyi; Wu, Jinhui; Hu, Yiqiao.

Affiliation

Zhou Z; State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing, China.
Tang X; State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing, China.
Zhang Y; State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing, China.
Hu Z; Center of Drug Discovery, China Pharmaceutical University, Nanjing 210009, China. Electronic address: zyhu@live.com.
Wu J; State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing, China. Electronic address: wuj@nju.edu.cn.
Hu Y; State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing, China. Electronic address: huyiqiao@nju.edu.cn.

Pharmacol Rep ; 66(6): 1140-7, 2014 Dec.

Article de En | MEDLINE | ID: mdl-25443747

Sujet(s)
Mots clés

Calcium antagonism; L-1416; P-gp inhibitor; Tumor therapy

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Phénéthylamines / Propylamines / Calcium / Glycoprotéine P / Antinéoplasiques Limites: Animals / Humans Langue: En Journal: Pharmacol Rep Sujet du journal: FARMACOLOGIA Année: 2014 Type de document: Article Pays d'affiliation: Chine

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google